With millions of people now taking GLP-1 medications, a natural question follows: is there an Ozempic for pets? Here’s what’s actually true as of November 2026, based on FDA, veterinary, and company sources.
The short answer: nothing is approved yet
No GLP-1 drug is FDA-approved for dogs or cats. The ASPCA’s March 2026 safety alert says none of the common human GLP-1 medications (semaglutide, tirzepatide, liraglutide, dulaglutide) “are currently approved for veterinary use.” CNBC reported in July 2026 that the two leading pet GLP-1 products in development are not approved and that there is “currently no commercial ‘Ozempic for cats.’”
Under federal law (the Animal Medicinal Drug Use Clarification Act), licensed veterinarians can, in certain conditions, prescribe approved human drugs for animals “extralabel” within a valid veterinarian-client-patient relationship. That is a decision for a veterinarian who has examined the animal. It is not something pet owners should attempt on their own.
What’s being studied for pets
OKV-119, a GLP-1 implant for cats
OKAVA Pharmaceuticals is developing OKV-119, a small implant placed under the skin that is designed to release exenatide, a GLP-1 receptor agonist, for up to six months. The company announced in December 2025 that the first cat was dosed in MEOW-1, a study of overweight or obese client-owned cats run under an FDA Center for Veterinary Medicine investigational new animal drug file. The study is listed in the AVMA’s veterinary clinical trials registry. We could not find published results as of November 21, 2026.
A once-weekly therapy studied at Cornell
CNBC reported that Akston Biosciences is sponsoring a Cornell University study of a once-weekly GLP-1 therapy in about 70 overweight or obese cats over roughly three months. Like OKV-119, it is investigational.
Why cats first?
Cats are hard to exercise and often resist diet changes, which is part of why developers see a need, according to CNBC’s reporting. Results from these trials will show whether the drugs are safe and work well enough in cats; there’s no guarantee either product reaches the market.
What about Loyal’s dog drugs?
Loyal is often mentioned alongside pet GLP-1s, but its drugs are different. Its lead program, LOY-002, is a daily prescription pill intended to extend healthy lifespan in senior dogs (10 years and older, at least 14 pounds) by targeting age-related metabolic dysfunction. It is not a GLP-1.
FDA’s Center for Veterinary Medicine has accepted two of the three major technical sections Loyal needs for conditional approval: reasonable expectation of effectiveness (February 2025) and target animal safety (January 2026). The manufacturing section is still pending, and Loyal’s pivotal effectiveness study, STAY, enrolled 1,300 dogs at 70 clinics. LOY-002 is not approved. Loyal is also developing LOY-001 and LOY-003 for large and giant breed dogs, both investigational.
Has a weight-loss drug for dogs ever been approved?
Yes, once. FDA approved Slentrol (dirlotapide) for managing obesity in dogs in December 2006. It wasn’t a GLP-1; it was a different type of drug that reduced fat absorption. A 2025 review in the American Journal of Veterinary Research notes it was available from 2007 through 2010, and that managing dogs on it was labor intensive and its gastrointestinal side effects were a problem. Its European marketing authorization was later withdrawn at the holder’s request, according to the European Medicines Agency. Today, veterinary weight management relies on diet, measured feeding, and activity plans set by your vet.
Keep your GLP-1 away from your pets
The more immediate pet risk is accidental exposure to your medication. The ASPCA reported rising GLP-1 exposures in pets and lists the most common signs:
- Vomiting
- Diarrhea
- Lethargy
- Decreased appetite
More serious problems, like low blood sugar and pancreatitis, are less likely but possible. Pets most often get exposed by chewing pens, vials, or pills, by being given a human dose by mistake, or by licking residue after an injection. A chewed pen can also cause injuries or a blockage.
The ASPCA’s advice:
- Store GLP-1 medications in closed cabinets, on high shelves, or in the refrigerator, separate from pet medications.
- Use sharps containers and pet-safe disposal.
- Be careful with over-the-counter “GLP-1-like” supplements. The ASPCA warns some contain ingredients dangerous to pets, including xylitol, 5-HTP, and caffeine or other stimulants.
If you think your pet got into a GLP-1 medication, contact your veterinarian. They may consult ASPCA Animal Poison Control at (888) 426-4435.
Helping an overweight pet today
Pet obesity is common, and the Association for Pet Obesity Prevention tracks it through yearly veterinary clinic surveys. Until a pet-specific drug is approved, the proven tools are the ones your veterinarian already uses: a body condition assessment, a target weight, measured portions or a therapeutic diet, and a realistic activity plan. Ask your vet about checking for conditions that can affect weight, such as hypothyroidism in dogs.
For the humans in the house
If you’re the one taking a GLP-1, our medication guides and GLP-1 pricing hub cover dosing schedules, side effects, and current prices for the approved human drugs.
Last updated November 21, 2026. We’ll update this page when pet GLP-1 trial results are published or FDA acts.
